Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01993108 · ClinicalTrials.gov registry record · Phase 4
Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT01993108 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 23 participants.
The verdict
NCT01993108, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal of this research is to understand the functioning of 'regulatory circuits' in the brain. We are also interested in how the medications methylphenidate and naltrexone affect these regulatory circuits. This research study will use a scanning technique known as functional magnetic resonance imaging (fMRI) which takes a special kind of picture of the brain that enables us to "see the brain at work". Adult participants will be given a one-time dose of either methylphenidate, naltrexone,or placebo before each fMRI scan session. The main purpose for this research is to better understand the functioning of regulatory circuits in healthy individuals and individuals with psychiatric disorders. This research may one day help us develop better treatments for these disorders.
Interventions
- DRUG Placebo
- DRUG Methylphenidate
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-10 |
| Est. Completion | 2017-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01993108
The ClinicalTrials.gov registry entry for NCT01993108 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01993108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01993108 about?
NCT01993108 is a clinical study titled "Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))". The goal of this research is to understand the functioning of 'regulatory circuits' in the brain. We are also interested in how the medications methylphenidate and naltrexone affect these regulatory circuits. This research study will use a scanning technique known as functional magnetic resonance im...
What is the current status of trial NCT01993108?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2013-10. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01993108?
The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01993108?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.